A cryo formulation-based microneedle device for transdermal delivery of bioactive therapeutic agents. The microneedle device includes: one or more microneedle patches each including an array of miniaturized needles, wherein each miniaturized needle defining a base end and a tip; and a substrate to which the base end of the array of miniaturized needles is attached or integrated thereto; wherein the microneedle patch is in a cryo status; wherein each of the one or more microneedle patch is adapted to be applied on a skin surface, in which the miniaturized needles penetrates into skin; wherein the miniaturized needles is further arranged to melt so as to release one or more bioactive therapeutic agents into the skin to achieve a targeted therapeutic effect; and wherein the bioactive therapeutic agents includes protein and/or antigens.

Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and/or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and/or essential tremors are also disclosed.

In some embodiments, data sensed and/or operational parameters used during a catheterization procedure are used in the motion frame-rate updating and visual rendering of a simulated organ geometry. The organ geometry is rendered as a virtual material using a software environment (preferably a graphical game engine) which applies simulated optical laws to material appearance parameters affecting the virtual material's visual appearance, as part of simulating a scene comprising the simulated organ geometry, and optionally also comprising simulated views of a catheter probe used for sensing and/or treatment. Optionally, measurements of and/or effects on tissue by sensing and/or commanded probe-tissue interactions are converted into material appearance changes, allowing dynamic visual simulation of intra-body states and/or events based on optionally non-visual input data. In some embodiments, physiology, motion physics, and/or other physical processes are simulated based on live inputs as part of associating material appearance properties to the simulated tissue's geometry.

Systems and methods for integrating a continuous glucose sensor, including a receiver, a medicament delivery device, a controller module, and optionally a single point glucose monitor are provided. Integration may be manual, semi-automated and/or fully automated.

This invention teaches a targeted apheresis method of treating a pregnant woman with preeclampsia, or who is predisposed to developing preeclampsia, utilizing immobilized binding agents contained within an apheresis device to remove sVEGFR-1 and sVEGFR-2, and one or more other harmful factors associated with preeclampsia selected from a list that includes: sEndoglin, Endothelin-1, TNF, IL-1, IL-6, IL-12, IL-18, digitalis-like factor, ouabain-like factor, marinobufagenin, .marinobufotoxenin, and telocinobufagin. The binding agents used are antibodies or aptamers or binding peptides. Reducing the concentration of sVEGFR-1, sVEGFR-2 and other harmful factors in the pregnant woman's blood using targeted apheresis will alleviate or delay the symptoms of preeclampsia, and thus postpone premature delivery of the baby so that the baby is born at term or as close to term as possible.

In a method for implantation of a physically stabilized aggregate of living cells or tissue fragment is injected into a channel provided in soft tissue filled with an aqueous gel. Also discloses are methods of stabilizing such aggregates and fragments and of forming such channel in soft tissue as well as means for carrying out the methods.

A skin regeneration therapy combining precise bioelectric signals, light, and biologics for skin treatment and regeneration. Precise bioelectric signals give clear instructions to the stimulated cell DNA/RNA to produce specific regenerative proteins on demand. Bioelectric signals give clear instructions to cell membranes on what to let in and what to let out and serve as an equivalent or surrogate of environmental stimuli to cause a cell action in response.

Systems, catheters, and methods for accessing and treating along the central nervous system are disclosed. An example method may manage inflammation of the patient to treat a condition of the patient by processing values related to one or more physiological parameters of a patent, identifying when an inflammation condition of the patient has reached a treatment condition based on the processed values, and automatically providing an indication that the inflammation condition has reached the treatment condition. An example indication may include actuation of a treatment protocol. The example method may be performed with an inflammation management system.

A method of adaptively determining one or more compensation factors in a closed-loop insulin delivery system comprising a continuous glucose level sensor, an insulin pump, and an insulin reservoir, where the system determines an insulin meal bolus taking into account an estimated amount of carbohydrates to be ingested, CHO, a difference between a currently sensed glucose level, G, and a glucose set point, G.sub.sp, and at least one compensation factor, ICR. The method comprises for each postprandial time period, t3-t4, determining a bolus offset value, B.sub.extra_new, by, if the sensed glucose level, G, exceeds a threshold level, Gl, determining a total insulin amount delivered by the insulin pump over the postprandial time period and setting the bolus offset value, B.sub.extra_new, to that total insulin amount, or if the sensed glucose level, G, is less than the threshold level, Gl, determining an offset between the sensed glucose level, G, and the glucose set point, G.sub.sp, and using that offset to determine the bolus offset value, B.sub.extra_new, adapting the compensation factor, ICR, over time using the determined the bolus offset value, B.sub.extra_new, in order to minimize the bolus offset value for subsequent postprandial time periods.